Welcome to our dedicated page for Entrada Therapeutics SEC filings (Ticker: TRDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Entrada Therapeutics’ SEC disclosures aren’t just numbers—they detail how the company’s EEV™ platform may unlock intracellular targets that traditional medicines miss. Yet decoding R&D expense lines, clinical trial updates, and collaboration milestones in a 300-page 10-K can feel overwhelming. If you’ve searched “Entrada Therapeutics SEC filings explained simply” or wondered how recent 8-K material events tie to Duchenne muscular dystrophy studies, you’re not alone.
Stock Titan bridges that gap. Our AI parses every Entrada Therapeutics quarterly earnings report 10-Q filing, flags cash-runway shifts, and converts scientific jargon into clear language. Receive Entrada Therapeutics Form 4 insider transactions real-time alerts to track when executives buy or sell shares. Need context for a sudden shelf registration? The platform links S-3 details to potential capital raises and provides concise, expert commentary. From the annual report 10-K simplified to each proxy statement executive compensation, you’ll find form-specific summaries, keyword search, and side-by-side comparisons — all updated the moment EDGAR posts.
Use these insights to:
- Monitor Entrada Therapeutics insider trading Form 4 transactions before key readouts
- Compare trial spending across quarters with our “cash used in operations” trend tool
- Spot risk-factor changes the instant they appear in an 8-K
Entrada Therapeutics, Inc. (NASDAQ: TRDA) – Form 144 filing dated 06/27/2025
The notice discloses that 5AM Ventures V, L.P., an affiliate of director Andrew J. Schwab, intends to sell up to 55,735 common shares of Entrada Therapeutics through TD Securities (USA) LLC on or about 06/27/2025. The shares to be sold represent roughly 0.15 % of the company’s 37,953,417 shares outstanding. The aggregate market value of the planned sale, based on the Form 144 calculation, is $385,128.85.
The securities were originally acquired on 09/28/2017 as a cash-funded venture investment. No other sales by the same party have occurred during the past three months, and the filer affirms that it possesses no undisclosed material adverse information regarding Entrada’s operations. The filing is marked “LIVE,” indicating an actual proposed disposition under SEC Rule 144, which permits resale of restricted securities if volume and timing conditions are met.
Investors typically monitor Form 144 filings because they may signal insider intentions to reduce holdings; however, the volume disclosed here is modest relative to Entrada’s float and does not, by itself, alter control dynamics. The declaration of no undisclosed adverse information and the use of a registered broker suggest the transaction is routine and compliant with securities regulations.
On 06/18/2025, Entrada Therapeutics (TRDA) filed a Form 4/A amending its prior insider-trading report. The filing discloses that director Peter S. Kim bought an additional 25,000 common shares on 05/13/2024 at a weighted-average price of $14.6804. This transaction was omitted from the original Form 4 filed on 05/16/2024, which had already reported a separate 25,000-share purchase on 05/14/2024 at $14.5869.
After including both purchases, Kim now directly owns 117,412 TRDA shares. No derivative securities were reported. The amendment corrects share totals and indicates that the director accumulated 50,000 shares over two consecutive trading days, a potential sign of insider confidence despite the minor reporting lapse.
FAQ
What is the current stock price of Entrada Therapeutics (TRDA)?
What is the market cap of Entrada Therapeutics (TRDA)?
What is the core focus of Entrada Therapeutics?
How does the EEV™ platform benefit drug development?
Which disease areas are targeted by Entrada Therapeutics?
What sets Entrada Therapeutics apart from traditional biopharmaceutical companies?
How does Entrada generate revenue?
What is the significance of the platform expansion in Entrada’s pipeline?
How does Entrada’s approach impact patient care?
What are the key challenges faced by Entrada Therapeutics?
